<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04712526</url>
  </required_header>
  <id_info>
    <org_study_id>Endostapler03</org_study_id>
    <nct_id>NCT04712526</nct_id>
  </id_info>
  <brief_title>Endostapler Gastric Bypass Study</brief_title>
  <official_title>Safety and Efficacy of the AEON™ Endostapler in Laparoscopic Roux-en-Y Gastric Bypass Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lexington Medical Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Lexington Medical Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this prospective, post-market study is to evaluate safety and efficacy of the&#xD;
      AEON™ Endostapler when used in laparoscopic Roux-en-Y gastric bypass surgery.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Stapler performance will be evaluated by incidence and degree of staple line bleeding from&#xD;
      endoscopic and laparoscopic images, evaluated by a third-party. The study will include 25&#xD;
      total consecutive cases of individuals undergoing a planned laparoscopic Roux-en-Y gastric&#xD;
      bypass (GB). The GB procedure will be performed according to institutional standard-of-care&#xD;
      and all subjects will undergo standard preoperative evaluation as well as post-operative&#xD;
      care.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 18, 2021</start_date>
  <completion_date type="Anticipated">January 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of reported device-related adverse events</measure>
    <time_frame>Within 30-day post-operative period</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Endoscopic staple line bleeding</measure>
    <time_frame>Within surgery</time_frame>
    <description>Incidence of intraoperative staple line bleeding from endoscopic images as measured by the provided bleeding severity scale - Bleeding Severity Scale for Endoscope Images (1: No bleeding, 5: Profuse Bleeding)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Laparoscopic staple line bleeding</measure>
    <time_frame>Within surgery</time_frame>
    <description>Incidence of intraoperative staple line bleeding from laparoscopic images as measured by the provided bleeding severity scale - Bleeding Severity Scale for Laparoscope Images (1: No bleeding, 5: Profuse Bleeding)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of intraoperative or postoperative blood transfusion</measure>
    <time_frame>Within 72 hours of surgery start time</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of product malfunction</measure>
    <time_frame>Within surgery</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">25</enrollment>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>AEON Endostapler</arm_group_label>
    <description>Stapling performed with AEON Endostapler</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>AEON Endostapler</intervention_name>
    <description>Surgery with AEON Endostapler</description>
    <arm_group_label>AEON Endostapler</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        25 subjects&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients undergoing planned laparoscopic Roux-en-Y gastric bypass&#xD;
&#xD;
          -  Informed consent for study obtained and signed from each subject&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Planned open surgical approach&#xD;
&#xD;
          -  Use of staple line reinforcement material (buttress)&#xD;
&#xD;
          -  Revision or other bariatric procedure&#xD;
&#xD;
          -  Patients with a bleeding disorder: known coagulopathy, or Platelets &lt;100,000, or PTT &gt;&#xD;
             45sec, or PT&gt; 15sec, or INR&gt;1.5&#xD;
&#xD;
          -  Patients with active HIV or Hepatitis B&#xD;
&#xD;
          -  Patients under the age of 18 on the date of the surgery&#xD;
&#xD;
          -  Patients who are pregnant&#xD;
&#xD;
          -  Patients using tobacco products within the last 2 weeks prior to surgery date&#xD;
&#xD;
          -  Patients using cortisone or related products within the last 2 weeks prior to surgery&#xD;
             date&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Annette Dunn</last_name>
    <phone>480-313-8505</phone>
    <email>annette@lexington-med.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Holyoke Medical Center</name>
      <address>
        <city>Holyoke</city>
        <state>Massachusetts</state>
        <zip>01040</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elana Davidson</last_name>
      <email>davidson_elana@holyokehealth.com</email>
    </contact>
    <investigator>
      <last_name>Yannis Raftopoulos, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>January 13, 2021</study_first_submitted>
  <study_first_submitted_qc>January 13, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 15, 2021</study_first_posted>
  <last_update_submitted>October 6, 2021</last_update_submitted>
  <last_update_submitted_qc>October 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

